Paper
A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome
Published Aug 1, 2018 · Grace Zhang, R. Whitney, Laura Wang
Annals of Clinical and Translational Neurology
84
Citations
1
Influential Citations
Abstract
Both Δ9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug‐resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary objective was to establish dosing and tolerability of TIL‐TC150 ‐ a cannabis plant extract produced by Tilray®, containing 100 mg/mL CBD and 2 mg/mL THC‐ in children with Dravet syndrome. Secondary objectives were to assess impact of therapy on seizures, electroencephalogram (EEG) and quality of life.
RCT
Rigorous Journal
Highly CitedTIL-TC150, a CBD/THC cannabis oil, shows potential in reducing seizures and improving quality of life in children with Dravet syndrome.
Full text analysis coming soon...